APO Research
Talk to an analyst

APO RESEARCH · REPORT

Klebsiella Pneumoniae Infection Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Klebsiella Pneumoniae Infection Drug Industry Research Report 2026

22 December 2025132 pages

Choose your research edition.

Industry ResearchKlebsiella Pneumoniae Infection Drug Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Klebsiella Pneumoniae Infection Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Klebsiella Pneumoniae Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Klebsiella Pneumoniae Infection Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Klebsiella Pneumoniae Infection Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Klebsiella Pneumoniae Infection Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Klebsiella Pneumoniae Infection Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Klebsiella Pneumoniae Infection Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Klebsiella Pneumoniae Infection Drug include Acies Bio doo, Appili Therapeutics, Debiopharm International SA, Evaxion Biotech ApS, FOB Synthesis Inc, ImmunoClin Corp, Innovation Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd and Melinta Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Klebsiella Pneumoniae Infection Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Klebsiella Pneumoniae Infection Drug Market by Company

Acies Bio doo

Appili Therapeutics

Debiopharm International SA

Evaxion Biotech ApS

FOB Synthesis Inc

ImmunoClin Corp

Innovation Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Pfizer Inc

F. Hoffmann-La Roche Ltd

Klebsiella Pneumoniae Infection Drug Segment by Type

ATI-1503

CA-824

CC-1807

Cefiderocol

Debio-1454

EBX-004

Others

Klebsiella Pneumoniae Infection Drug Segment by Application

Hospital

Clinic

Others

Klebsiella Pneumoniae Infection Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Klebsiella Pneumoniae Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Klebsiella Pneumoniae Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Klebsiella Pneumoniae Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Klebsiella Pneumoniae Infection Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Klebsiella Pneumoniae Infection Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Klebsiella Pneumoniae Infection Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Klebsiella Pneumoniae Infection Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Klebsiella Pneumoniae Infection Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Klebsiella Pneumoniae Infection Drug Revenue of Manufacturers (2021-2026) Table 9. Global Klebsiella Pneumoniae Infection Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Klebsiella Pneumoniae Infection Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Klebsiella Pneumoniae Infection Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Klebsiella Pneumoniae Infection Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Klebsiella Pneumoniae Infection Drug, Product Type & Application Table 14. Global Klebsiella Pneumoniae Infection Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Klebsiella Pneumoniae Infection Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Acies Bio doo Company Information Table 19. Acies Bio doo Business Overview Table 20. Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio Table 22. Acies Bio doo Recent Developments Table 23. Appili Therapeutics Company Information Table 24. Appili Therapeutics Business Overview Table 25. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio Table 27. Appili Therapeutics Recent Developments Table 28. Debiopharm International SA Company Information Table 29. Debiopharm International SA Business Overview Table 30. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio Table 32. Debiopharm International SA Recent Developments Table 33. Evaxion Biotech ApS Company Information Table 34. Evaxion Biotech ApS Business Overview Table 35. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 37. Evaxion Biotech ApS Recent Developments Table 38. FOB Synthesis Inc Company Information Table 39. FOB Synthesis Inc Business Overview Table 40. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 42. FOB Synthesis Inc Recent Developments Table 43. ImmunoClin Corp Company Information Table 44. ImmunoClin Corp Business Overview Table 45. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio Table 47. ImmunoClin Corp Recent Developments Table 48. Innovation Pharmaceuticals Inc Company Information Table 49. Innovation Pharmaceuticals Inc Business Overview Table 50. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 52. Innovation Pharmaceuticals Inc Recent Developments Table 53. Kyorin Pharmaceutical Co Ltd Company Information Table 54. Kyorin Pharmaceutical Co Ltd Business Overview Table 55. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 57. Kyorin Pharmaceutical Co Ltd Recent Developments Table 58. Melinta Therapeutics Inc Company Information Table 59. Melinta Therapeutics Inc Business Overview Table 60. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 62. Melinta Therapeutics Inc Recent Developments Table 63. Nosopharm SAS Company Information Table 64. Nosopharm SAS Business Overview Table 65. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 67. Nosopharm SAS Recent Developments Table 68. Peptilogics Inc Company Information Table 69. Peptilogics Inc Business Overview Table 70. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 72. Peptilogics Inc Recent Developments Table 73. Phico Therapeutics Ltd Company Information Table 74. Phico Therapeutics Ltd Business Overview Table 75. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 77. Phico Therapeutics Ltd Recent Developments Table 78. Sarepta Therapeutics Inc Company Information Table 79. Sarepta Therapeutics Inc Business Overview Table 80. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 82. Sarepta Therapeutics Inc Recent Developments Table 83. Shionogi & Co Ltd Company Information Table 84. Shionogi & Co Ltd Business Overview Table 85. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 87. Shionogi & Co Ltd Recent Developments Table 88. Syntiron LLC Company Information Table 89. Syntiron LLC Business Overview Table 90. Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio Table 92. Syntiron LLC Recent Developments Table 93. Tetraphase Pharmaceuticals Inc Company Information Table 94. Tetraphase Pharmaceuticals Inc Business Overview Table 95. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 97. Tetraphase Pharmaceuticals Inc Recent Developments Table 98. Pfizer Inc Company Information Table 99. Pfizer Inc Business Overview Table 100. Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 102. Pfizer Inc Recent Developments Table 103. F. Hoffmann-La Roche Ltd Company Information Table 104. F. Hoffmann-La Roche Ltd Business Overview Table 105. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 107. F. Hoffmann-La Roche Ltd Recent Developments Table 108. Global Klebsiella Pneumoniae Infection Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2026) & (k units) Table 110. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2021-2026) Table 111. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2027-2032) & (k units) Table 112. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2027-2032) Table 113. Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2021-2026) Table 115. Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2027-2032) Table 117. North America Klebsiella Pneumoniae Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 119. North America Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 120. North America Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Klebsiella Pneumoniae Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Klebsiella Pneumoniae Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 124. Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 125. Europe Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Klebsiella Pneumoniae Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Klebsiella Pneumoniae Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 129. Asia Pacific Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 130. Asia Pacific Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Klebsiella Pneumoniae Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Klebsiella Pneumoniae Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 134. South America Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 135. South America Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Klebsiella Pneumoniae Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 139. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country (2027-2032) & (k units) Table 140. Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 143. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (k units) Table 144. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2021-2026) Table 145. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2027-2032) Table 146. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2021-2026) Table 149. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2027-2032) Table 150. Global Klebsiella Pneumoniae Infection Drug Price by Type (2021-2026) & (US$/unit) Table 151. Global Klebsiella Pneumoniae Infection Drug Price by Type (2027-2032) & (US$/unit) Table 152. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 153. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (k units) Table 154. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2021-2026) Table 155. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2027-2032) Table 156. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2021-2026) Table 159. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2027-2032) Table 160. Global Klebsiella Pneumoniae Infection Drug Price by Application (2021-2026) & (US$/unit) Table 161. Global Klebsiella Pneumoniae Infection Drug Price by Application (2027-2032) & (US$/unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Klebsiella Pneumoniae Infection Drug Distributors List Table 165. Klebsiella Pneumoniae Infection Drug Customers List Table 166. Klebsiella Pneumoniae Infection Drug Industry Trends Table 167. Klebsiella Pneumoniae Infection Drug Industry Drivers Table 168. Klebsiella Pneumoniae Infection Drug Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Klebsiella Pneumoniae Infection Drug Product Image Figure 5. Global Klebsiella Pneumoniae Infection Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Klebsiella Pneumoniae Infection Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Klebsiella Pneumoniae Infection Drug Sales (2021-2032) & (k units) Figure 8. Global Klebsiella Pneumoniae Infection Drug Average Price (US$/unit) & (2021-2032) Figure 9. ATI-1503 Product Image Figure 10. CA-824 Product Image Figure 11. CC-1807 Product Image Figure 12. Cefiderocol Product Image Figure 13. Debio-1454 Product Image Figure 14. EBX-004 Product Image Figure 15. Others Product Image Figure 16. Hospital Product Image Figure 17. Clinic Product Image Figure 18. Others Product Image Figure 19. Global Klebsiella Pneumoniae Infection Drug Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Klebsiella Pneumoniae Infection Drug, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Klebsiella Pneumoniae Infection Drug Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Klebsiella Pneumoniae Infection Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Klebsiella Pneumoniae Infection Drug Sales by Region in 2025 Figure 25. Global Klebsiella Pneumoniae Infection Drug Revenue by Region in 2025 Figure 26. North America Klebsiella Pneumoniae Infection Drug Market Size by Country in 2025 Figure 27. North America Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2032) Figure 28. North America Klebsiella Pneumoniae Infection Drug Revenue Market Share by Country (2021-2032) Figure 29. United States Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Klebsiella Pneumoniae Infection Drug Market Size by Country in 2025 Figure 33. Europe Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2032) Figure 34. Europe Klebsiella Pneumoniae Infection Drug Revenue Market Share by Country (2021-2032) Figure 35. Germany Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Klebsiella Pneumoniae Infection Drug Market Size by Country in 2025 Figure 46. Asia Pacific Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Klebsiella Pneumoniae Infection Drug Revenue Market Share by Country (2021-2032) Figure 48. China Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Klebsiella Pneumoniae Infection Drug Market Size by Country in 2025 Figure 57. South America Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2032) Figure 58. South America Klebsiella Pneumoniae Infection Drug Revenue Market Share by Country (2021-2032) Figure 59. Brazil Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size by Country in 2025 Figure 63. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue Market Share by Country (2021-2032) Figure 65. Egypt Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Klebsiella Pneumoniae Infection Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2021-2032) Figure 71. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2021-2032) Figure 72. Global Klebsiella Pneumoniae Infection Drug Price (US$/unit) by Type (2021-2032) Figure 73. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2021-2032) Figure 74. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2021-2032) Figure 75. Global Klebsiella Pneumoniae Infection Drug Price (US$/unit) by Application (2021-2032) Figure 76. Klebsiella Pneumoniae Infection Drug Value Chain Figure 77. Klebsiella Pneumoniae Infection Drug Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • ATI-1503
  • CA-824
  • CC-1807
  • Cefiderocol
  • Debio-1454
  • EBX-004
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Acies Bio doo
  • Appili Therapeutics
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • FOB Synthesis Inc
  • ImmunoClin Corp
  • Innovation Pharmaceuticals Inc
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Peptilogics Inc
  • Phico Therapeutics Ltd
  • Sarepta Therapeutics Inc
  • Shionogi & Co Ltd
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Klebsiella Pneumoniae Infection Drug Market Size (2021-2032)
  4. 2.2.2 Global Klebsiella Pneumoniae Infection Drug Sales (2021-2032)
  5. 2.2.3 Global Klebsiella Pneumoniae Infection Drug Market Average Price (2021-2032)
  6. 2.3 Klebsiella Pneumoniae Infection Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 ATI-1503
  9. 2.3.3 CA-824
  10. 2.3.4 CC-1807
  11. 2.3.5 Cefiderocol
  12. 2.3.6 Debio-1454
  13. 2.3.7 EBX-004
  14. 2.3.8 Others
  15. 2.4 Klebsiella Pneumoniae Infection Drug by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 Hospital
  18. 2.4.3 Clinic
  19. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Klebsiella Pneumoniae Infection Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Klebsiella Pneumoniae Infection Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Klebsiella Pneumoniae Infection Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Klebsiella Pneumoniae Infection Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Klebsiella Pneumoniae Infection Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Klebsiella Pneumoniae Infection Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Klebsiella Pneumoniae Infection Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Klebsiella Pneumoniae Infection Drug, Established Date
  9. 3.9 Global Klebsiella Pneumoniae Infection Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Acies Bio doo
  2. 4.1.1 Acies Bio doo Company Information
  3. 4.1.2 Acies Bio doo Business Overview
  4. 4.1.3 Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio
  6. 4.1.5 Acies Bio doo Recent Developments
  7. 4.2 Appili Therapeutics
  8. 4.2.1 Appili Therapeutics Company Information
  9. 4.2.2 Appili Therapeutics Business Overview
  10. 4.2.3 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio
  12. 4.2.5 Appili Therapeutics Recent Developments
  13. 4.3 Debiopharm International SA
  14. 4.3.1 Debiopharm International SA Company Information
  15. 4.3.2 Debiopharm International SA Business Overview
  16. 4.3.3 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio
  18. 4.3.5 Debiopharm International SA Recent Developments
  19. 4.4 Evaxion Biotech ApS
  20. 4.4.1 Evaxion Biotech ApS Company Information
  21. 4.4.2 Evaxion Biotech ApS Business Overview
  22. 4.4.3 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio
  24. 4.4.5 Evaxion Biotech ApS Recent Developments
  25. 4.5 FOB Synthesis Inc
  26. 4.5.1 FOB Synthesis Inc Company Information
  27. 4.5.2 FOB Synthesis Inc Business Overview
  28. 4.5.3 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  30. 4.5.5 FOB Synthesis Inc Recent Developments
  31. 4.6 ImmunoClin Corp
  32. 4.6.1 ImmunoClin Corp Company Information
  33. 4.6.2 ImmunoClin Corp Business Overview
  34. 4.6.3 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio
  36. 4.6.5 ImmunoClin Corp Recent Developments
  37. 4.7 Innovation Pharmaceuticals Inc
  38. 4.7.1 Innovation Pharmaceuticals Inc Company Information
  39. 4.7.2 Innovation Pharmaceuticals Inc Business Overview
  40. 4.7.3 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  42. 4.7.5 Innovation Pharmaceuticals Inc Recent Developments
  43. 4.8 Kyorin Pharmaceutical Co Ltd
  44. 4.8.1 Kyorin Pharmaceutical Co Ltd Company Information
  45. 4.8.2 Kyorin Pharmaceutical Co Ltd Business Overview
  46. 4.8.3 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  48. 4.8.5 Kyorin Pharmaceutical Co Ltd Recent Developments
  49. 4.9 Melinta Therapeutics Inc
  50. 4.9.1 Melinta Therapeutics Inc Company Information
  51. 4.9.2 Melinta Therapeutics Inc Business Overview
  52. 4.9.3 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  54. 4.9.5 Melinta Therapeutics Inc Recent Developments
  55. 4.10 Nosopharm SAS
  56. 4.10.1 Nosopharm SAS Company Information
  57. 4.10.2 Nosopharm SAS Business Overview
  58. 4.10.3 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio
  60. 4.10.5 Nosopharm SAS Recent Developments
  61. 4.11 Peptilogics Inc
  62. 4.11.1 Peptilogics Inc Company Information
  63. 4.11.2 Peptilogics Inc Business Overview
  64. 4.11.3 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  66. 4.11.5 Peptilogics Inc Recent Developments
  67. 4.12 Phico Therapeutics Ltd
  68. 4.12.1 Phico Therapeutics Ltd Company Information
  69. 4.12.2 Phico Therapeutics Ltd Business Overview
  70. 4.12.3 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  72. 4.12.5 Phico Therapeutics Ltd Recent Developments
  73. 4.13 Sarepta Therapeutics Inc
  74. 4.13.1 Sarepta Therapeutics Inc Company Information
  75. 4.13.2 Sarepta Therapeutics Inc Business Overview
  76. 4.13.3 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  78. 4.13.5 Sarepta Therapeutics Inc Recent Developments
  79. 4.14 Shionogi & Co Ltd
  80. 4.14.1 Shionogi & Co Ltd Company Information
  81. 4.14.2 Shionogi & Co Ltd Business Overview
  82. 4.14.3 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  84. 4.14.5 Shionogi & Co Ltd Recent Developments
  85. 4.15 Syntiron LLC
  86. 4.15.1 Syntiron LLC Company Information
  87. 4.15.2 Syntiron LLC Business Overview
  88. 4.15.3 Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio
  90. 4.15.5 Syntiron LLC Recent Developments
  91. 4.16 Tetraphase Pharmaceuticals Inc
  92. 4.16.1 Tetraphase Pharmaceuticals Inc Company Information
  93. 4.16.2 Tetraphase Pharmaceuticals Inc Business Overview
  94. 4.16.3 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  96. 4.16.5 Tetraphase Pharmaceuticals Inc Recent Developments
  97. 4.17 Pfizer Inc
  98. 4.17.1 Pfizer Inc Company Information
  99. 4.17.2 Pfizer Inc Business Overview
  100. 4.17.3 Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  102. 4.17.5 Pfizer Inc Recent Developments
  103. 4.18 F. Hoffmann-La Roche Ltd
  104. 4.18.1 F. Hoffmann-La Roche Ltd Company Information
  105. 4.18.2 F. Hoffmann-La Roche Ltd Business Overview
  106. 4.18.3 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  108. 4.18.5 F. Hoffmann-La Roche Ltd Recent Developments
5 Global Klebsiella Pneumoniae Infection Drug Market Scenario by Region
  1. 5.1 Global Klebsiella Pneumoniae Infection Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2027-2032
  5. 5.3 Global Klebsiella Pneumoniae Infection Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Region: 2027-2032
  8. 5.4 North America Klebsiella Pneumoniae Infection Drug Market Facts & Figures by Country
  9. 5.4.1 North America Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Klebsiella Pneumoniae Infection Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Klebsiella Pneumoniae Infection Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Klebsiella Pneumoniae Infection Drug Market Facts & Figures by Country
  41. 5.7.1 South America Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Klebsiella Pneumoniae Infection Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Klebsiella Pneumoniae Infection Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Klebsiella Pneumoniae Infection Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Klebsiella Pneumoniae Infection Drug Value Chain Analysis
  2. 8.1.1 Klebsiella Pneumoniae Infection Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Klebsiella Pneumoniae Infection Drug Production Mode & Process
  5. 8.2 Klebsiella Pneumoniae Infection Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Klebsiella Pneumoniae Infection Drug Distributors
  8. 8.2.3 Klebsiella Pneumoniae Infection Drug Customers
9 Global Klebsiella Pneumoniae Infection Drug Analyzing Market Dynamics
  1. 9.1 Klebsiella Pneumoniae Infection Drug Industry Trends
  2. 9.2 Klebsiella Pneumoniae Infection Drug Industry Drivers
  3. 9.3 Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges
  4. 9.4 Klebsiella Pneumoniae Infection Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst